Plant-derived leading compounds for chemotherapy of human immunodefiency virus (HIV) infection - An update (1998-2007)

Planta Medica

Volumn 74, Issue 11, 2008, Pages 1323-1337

  Cos, Paul ^a   Maes, Louis ^a,b   Vlietinck, Arnold ^a   Pieters, Luc ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Anti AIDS products; Anti HIV properties; Antiviral activity; HIV; Natural products; Plant derived products

Indexed keywords

18 METHOXYCORONARIDINE; 3 INDOLECARBOXYLIC ACID; ALKALOID DERIVATIVE; ALPHA HOMONOJIRIMYCIN; ANTIVIRUS AGENT; CALANOLIDE A; CEPHARANTHINE; CHALCONE DERIVATIVE; COUMARIN; DEXTRAN SULFATE; HYDROXYPANDURATIN; IBOGAINE; KHELLOLATONE; LAMIVUDINE; LIGNAN DERIVATIVE; LYCORINE; MICHELLAMINE A; MICHELLAMINE B; MICHELLAMINE C; NELFINAVIR; OCTADEHYDROMICHELLAMINE; PLANT MEDICINAL PRODUCT; POLYSACCHARIDE SULFATE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SESQUITERPENE; SIAMENOL; TANNIN DERIVATIVE; TAXIFOLIN; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DIZZINESS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; NAUSEA; NONHUMAN; REVIEW; TASTE DISORDER; TREATMENT INDICATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ALKALOIDS; ANTI-HIV AGENTS; CARBOHYDRATES; FLAVONOIDS; HIV INFECTIONS; HUMANS; LIGNANS; PHENOLS; PHYTOTHERAPY; PLANT PROTEINS; PLANTS; TANNINS; TERPENES;

EID: 52949147153     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081314     Document Type: Review

References (195)

1. Vlietinck AJ, De Bruyne T, Apers S, pieters L. Plant-derived leading compounds for chemotherapy of human immunodefiency virus (HIV) in-fection. Planta Med 1998; 64: 97-109
2. Matthee G, Wright AD, König G. HIV reverse transcriptase inhibitors of natural origin. Planta Med 1999; 65: 493-506
3. Cos P. Vanden Berghe D, De Bruyne T, Vlietinck AJ. Plant substances as antiviral agents: An update (1997-2001). Curr Org Chem 2003; 7: 1163-80
4. Cos P, Maes L, Vanden Berghe D, Hermans N, Pieters L, Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod 2004; 67: 284-93
5. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6: 1001-18
6. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-73
7. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Dis-ov2007; 6: 959-66
8. Cos P, Vlietinck AJ, Vanden Berghe D, Maes L. Anti-infective potential of natural products: how to develop a stronger in vitro proof-of-concept. J Ethnopharmacol 2006; 106: 290-302
9. White EL, Chao WR, Ross LJ, Borhani DW, Hobbs PD, Upender V et al. Michellamine alkaloids inhibit protein kinase C. Arch Biochem Biophys 1999; 365: 25-30
10. Hallock YE, Manfredi K, Dai J, Cardellina JH II, Gulakowski RJ, McMahon JB et al. Michellamines D - F, new HIV-inhibitory dimeric naphthyliso-quinoline alkaloids, and korupensamine E, a new antimalarial monomer, from Ancistrocladus korupensis. J Nat Prod 1997; 60: 677-83
11. Bringmann G, Holenz J, Weirich R, Rübenacker M, Funke C, Boyd MR et al. First synthesis of the antimalarial naphthylisoquinoline alkaloid dioncophylline C, and its unnatural anti-HIV dimer, jozimine C. Tetrahedron 1998; 54: 497-512
12. Bringmann G, Wenzel M, Ross Kelly T, Boyd MR, Gulakowski RJ, Kaminsky R. Octadehydromichellamine, a structural analog of the anti-HIV michellamines without centrochirality. Tetrahedron 1999; 55: 1731-40
13. Karpas A, Fleet GWJ, Dwek RA, Petursson S, Namgoong SK, Ramsden NG et al. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA 1988; 85: 9229-33
14. Watson AA, Fleet GWJ, Asano N, Molyneux RJ, Nash RJ. Polyhydroxylated alkaloids - natural occurrence and therapeutic applications. Phyto-chemistry 2001; 56: 265-95
15. Taylor DL, Nash R, Fellows LE, Kang MS, Tyms AS. Naturally occurring pyrrolizidines: Inhibition of α-glucosidase 1 and anti-HIV activity of one stereoisomer. Antiviral Chem Chemother 1992; 3: 273-7
16. Asano N, Nishida M, Kato A, Kizu H, Matsui K, Shimada Y et al. Homono-jirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem 1998; 41:2565-71
17. Matsuno T, Orita K, Edashige K, Kobuchi H, Sato EF, Inouye B et al. Inhibition of active oxygen generation in guinea-pig neutrophils by bisco-claurine alkaloids. Biochem Pharmacol 1990; 39: 1255-9
18. Kondo Y, Imai Y, Hojo H, Hashimoto Y, Nozoe S. Selective inhibition of T-cell dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. Int J Immunopharmacol 1992; 14: 1181-6
19. Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharantine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci 2007; 80: 1073-9
20. Legrand-Poels S, Vaira D, Pincemail J, Van de Vorst A, Piette J. Activation of human immunodeficiency virus type 1 by oxidative stress. AIDS Res Hum Retroviruses 1990; 6: 1389-97
21. Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses 1998; 14: 1239-45
22. Longanga Otshudi A, Apers S, Pieters L, Claeys M, Pannecouque C, De Clercq E et al. Biologically active bisbenzylisoquinoline alkaloids from the root bark of Epinetrum villosum. j Ethopharmacol 2005; 102: 89-94
23. Duan H, Takaishi Y, Imakura Y. Jia Y, Li D, Cosentino M et al. Sesquiterpene alkaloids from Tripterygium hypoglaucum and Tripterygium wilfordii: A new class of potent anti-HIV agents. J Nat Prod 2000; 63: 357-61
24. Ishida j, Wang HK, Oyama M, Cosentino ML, Hu CQ. Lee KH. Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives. J Nat Prod 2001; 64: 958-60
25. Meragelman KM, McKee TC, Boyd MR. Siamenol, a new carbazole alkaloid from Murraya siamensis. J Nat Prod 2000; 63: 427-8
26. Kongkathip B, Kongkathip N. Sunthitikawinsakul A, Napaswat C. Yoosook C. Anti-HIV-1 constituents from Clausena excavata: Part II. Carbazoles and a pyranocoumarin. Phytother Res 2005: 19: 728-31
27. Xu Z. Chang FR, Wang HK. Kashiwada Y, McPhail AT. Bastow KF et al. Anti-HIV agents 45 and antitumour agents 205. Two new sesquiterpenes, leitneridanins A and B. and the cytotoxic and anti-HIV principles from Leitneria floridana. J Nat Prod 2000: 63: 1712-5
28. Hsieh PW, Chang FR, Lee KH, Hwang TL Chang SM, Wu YC. A new anti-HIV alkaloid, drymaritin, and a new C-glycoside flavonoid, diandrofla-vone, from Drymaria diandra. J Nat Prod 2004; 67: 1175-7
29. Silva EM, Cirne-Santos CC, Frugulhetti ICPP, Calvao-Castro B, Saraiva EMB, Kuehne ME et al. Anti-HIV activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Med 2004; 70: 808-12
30. Leven M, Vanden Berghe DA, Vlietinck AJ. Plant antiviral agents IV. Influence of lycorine on growth pattern of three animal viruses. Planta Med 1983: 49: 109-14
31. Szlavik L CyurisA, Minarovits J, Forgo P, Molnar J, Hohmann J. Alkaloids from Leucojum vernum and antirettroviral activity of Amaryllidaceae alkaloids. Planta Med 2004; 70: 871-3
32. Wu PL, Lin FW, Wu TS, Kuoh CS, Lee KH, Lee SJ. Cytotoxic and anti-HIV principles from the rhizomes of Begonia nantoensis. Chem Pharm Bull 2004; 52: 345-9
33. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 tat protein. EMBO J 1991: 10: 1733-9
34. Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, Ciacca M et al. Pentosan sulfate as an inhibitor of extracellular HIV-1 tat. J Biol Chem 2001; 25: 22420-5
35. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D et al. Interaction of HIV-1 tat protein with heparin. J Biol Chem 1997; 17: 11313-20
36. Watson K. Gooderham NJ, Davies DS, Edwards RJ. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Biochem Pharmacol 1999; 57: 775-83
37. Lüscher-Mattli M. Polyanions - a lost chance in the fight against HIV and other virus diseases? Antiviral Chem Chemother 2000; 11: 249-59
38. Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol 1997; 29: 497-511
39. Esté JA, Schols D, De Vreese K, Van Laethem K. Vandamme AM, Desmyter J et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gpl20 glycoprotein. Mol Pharmacol 1997; 52:98-104
40. Abrams DI, Kuno S. Wong R, Jeffords K, Nash M, Molaghan JB et al. Oral dextran sulfate (UA001) in the treatment of the acquired immunode-ficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110: 183-8
41. Flexner C, Barditch-Crovo PA, Kornhauser DM. Farzadegan H, Nerhood LJ, Chaisson RE et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2544-50
42. Hiebert LM, Wice SM, Jaques LB, Williams KE, Conly JM. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J Lab Clin Med 1999; 133: 161-70
43. Shaunak S, Thornton M. John S, Teo I, Peers E, Mason P et al. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulfate in patients with AIDS. AIDS 1998; 12: 399-409
44. De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 2000; 20:323-49
45. Hoshino T, Hayashi T, Hayashi K, Hamada J, Lee JB, Sankawa U. An anti-virally active sulfated polysaccharide from Sargassum horneri (Turner) C. Agardh. Biol Pharm Bull 1998; 21: 730-4
46. Lee JB, Hayashi K, Hayashi T, Sankawa U, Maeda M. Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum. Planta Med 1999; 65: 439-41.
47. Haslin C, Lahaye M, Pellegrini M, Chermann JC In vitro anti-HIV activity of sulfated cell-wall polysaccharides from gametic, carposporic and tetrasporic stages of the Mediterranean red alga Asparagopsis armata. Planta Med 2001; 67: 301-5
48. Rechter S. König T, Auerochs S, Thulke S, Walter H, Dömenburh H et al. Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res 2006; 72: 197-206
49. Kashman Y, Custafson KR, Fuller RW, Cardellina JH, McMahon JB, Currens MJ et al. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 1992; 35: 2735-43
50. Ishikawa T. Anti-HIV-1 active Calophyllum coumarins: distribution. chemistry and activity. Heterocycles 2000; 53: 453-74
51. Zembower DE, Liao S, Flavin MT. Xu ZQ, Stup TL Buckheit RW et al. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10, 11-dimethyldihydropyran-12-ol ring (ring C)1. J Med Chem 1997: 40: 1005-17
52. Dharmaratne HRW. Tan GT, Marasinghe GPK. PezzutoJM. Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. Planta Med 2002; 68: 86-7
53. Yu D, Suzuki M, Xie L Morris-Natschke SL Lee KH. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 2003; 23: 322-45
54. Dharmaratne HRW, Wanigasekera WMAP, Mata-Greenwood E. Pezzuto JM. Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordato-oblongum. Planta Med 1998; 64: 460-1
55. Quan Y, Motakis D, Buckheit R, Xu ZQ, Flavin MT, Parniak MA et al. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antiviral Ther 1999; 4: 203-9
56. Buckheit RW, White EL Fliakis-Boltz V, Russell J, Stup TL Kinjerski TL et al. Unique anti-human immunodeficiency virus activities of the non-nucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999; 43: 1827-34
57. Buckheit RW, Russell J, Xu ZQ, Flavin M. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HOV-1 replication. Antiviral Chem Chemother 2000; 11: 321-7
58. Xu ZQ, Hollingshead MG. Borget S, Elder C, Khilevich A, Flavin MT. In vivo activity of (+)-calanoIide A in the hollow fiber mouse model. Bioorg Med Chem Lett 1999; 9: 133-8
59. Xu ZQ, Norris KJ, Weinberg DS, Kardatzke J, Wertz P, Frank P et al. Quantification of(+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human. J Chromatogr B 2000; 742: 267-75
60. Newman RA, Chen W, Madden TL. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci 1998; 87: 1077-80
61. Sorbera LA, Castaner RM. Calanolide A. Drugs Fut 2001; 26: 285-6
62. Creagh T, Ruckle JL. Tolbert DT, Giltner J, Eiznhamer DA, Dutta B et al. Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001; 45: 1379-86
63. Kostova I, Raleva S, Genova P, Argirova R. Structure-activity relationships of synthetic coumarins as HIV-1 inhibitors. Bioorg Chem Appl 2006: 68274: 1-9
64. Chen Y, Zhang Q, Zhang B, Xia P, Xia Y, Yang ZY et al. Anti-AIDS agents. Part 56: Synthesis and anti-HIV activity of 7-thia-di-O-(-)- camphanoyl-(+)-cis-khellolactone (7-thia-DCK) analogs. Bioorg Med Chem 2004; 12:6383-7
65. Marquez N, Sancho R, Bedoya LM, Alcami J, Lopez-Perez JL San Feliciano A et al. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kB pathway. Antiviral Res 2005; 66: 137-45
66. Kitamura K, Honda M, Yoshizaki H, Yamamoto S, Nakane H, Fukushima M et al. Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res 1998:37: 131-40
67. Xu HX, Wan M. Dong H, But PPH, Foo LY. Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol Pharm Bull 2000; 23: 1072-6
68. Kim HJ, Woo ER, Shin CG, Park H. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1 )integrase. J Nat Prod 1998; 61: 145-8
69. Critchfield JW, Coligan JE, Folks TM, Butera ST. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc Natl Acad Sci USA 1997; 94: 6110-5
70. Haneda E, Furuya T, Asai S, Morikawa Y, Ohtsuki K. Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro. Biochem Biophys Res Commun 2000;275:434-9
71. Harada S, Haneda E, Maekawa T, Morikawa Y, Funayama S, Nagata N et al. Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol Pharm Bull 1999; 22: 1122-6
72. Wu JH, Wang XH, Yi YH, Lee KH. Anti-AIDS agents 54. A potent anti-HIV chalcone and Flavonoids from genus Desmos. Bioorg Med Chem Lett 2003; 13: 1813-5
73. Nakagawa-Coto K, Lee KH. Anti-AIDS agents 68. The first total synthesis of a unique potent anti-HIV chalcone from genus Desmos. Tetrahedron Lett 2006; 47: 8263-6
74. Cheenpracha S, Karalai C, Ponglimanont C, Subhadhirasakul S, Tewtrakul S. Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata. Bioorg Med Chem 2006; 14: 1710-4
75. Mahmood N, Piacente S, Burke A, Khan A, Pizza C. Constituents of Cuscuta reflexa are anti-HIV agents. Antiviral Chem Chemother 1997; 8: 70-4
76. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 2002; 53: 19-34
77. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol 2006; 118: 1369-74
78. Rowley DC, Hansen MST, Rhodes D, Sotriffer CA, Ni H, McCammon JA et al. Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA in-tegrase. Bioorg Med Chem 2002; 10: 3619-25
79. Croweiss A, Cardellina JH, Boyd MR. HIV-inhibitory prenylated xan-thones and flavones from Madura tinctoria. J Nat Prod 2000; 63: 1537-9
80. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: recent developments. Planta Med 2003; 69: 589-99
81. Wang Q, Ding ZH, Liu JK, Zheng YT. Xanthohumol, a novel anti-HIV-1 agent purified from hops Humulus lupulus. Antiviral Res 2004; 64: 189-94
82. Lin YM, Anderson H, Flavin MT, Pai YHS, Mata-Creenwood E, Pengsuparp T et al. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 1997; 60: 884-8
83. Reutrakul V, Ningnuek N, Pohmakotr M, Yoosook C, Napaswad C, Kasisit J et al. Anti HIV-1 flavonoid glycosides from Ochna integerrima. Planta Med 2007; 73: 683-8
84. Alves CN, Pinheiro JC, Camargo AJ, de Souza AJ, Carvalho RB, da Silva ABF. A quantum chemical and statistical study of flavonoid compounds with anti-HIV activity. J Mol Struct (Theochem) 1999; 491: 123-31
85. Mamas A, Deretey E, Ferretti FH, Estrada MR, Csizmadia IG. Structural analysis of flavonoids with anti-HIV activity. J Mol Struct (Theochem) 2000; 504: 171-9
86. Alves CN, Pinheiro JC, Camargo AJ, Ferreira MMC, Romero RAF, da Silva ABF. A multiple linear regression and partial least squares study of flavonoid compounds with anti-HIV activity. J Mol Struct (Theochem) 2001;541:81-8
87. Tao J, Qinxue H, Yang J, Li R, Li X, Lu C et al. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res 2007; 75: 227-33
88. He Y, Zeng S. Transport characteristics of rutin deca (H-)sulfonate sodium across Caco-2 cell monolayers. J Pharm Pharmacol 2005; 57: 1297-303
89. Wang XJ, Jin YX, Ying JY, Zeng S, Tao TW. Determination of rutin deca (H-)sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction. J Chromatogr B 2006; 833: 231-5
90. Charlton JL. Antiviral activity of lignans. J Nat Prod 1998; 61: 1447-51
91. Valsaraj R, Pushpangadan P, Smitt UW, Adersen A, Christensen SB, Sittie A et al. New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. J Med Chem 1997; 60: 739-42
92. Kuo YH, Li SY, Huang RL, Wu MD, Huang HC, Lee KH. Schizarin B, C, D and E, four new lignans from Kadsura matsudai and their antihepatitis activities. J Nat Prod 2001; 64: 487-90
93. Hoang VD, Tan GT, Zhang HJ, Tamez PA, Van Hung N, Cuong NM et al. Natural anti-HIV agents - part 1: (+)-demethoxyepiexcelsin and ver-ticillatol from Litsea verticillata. Phytochemistry 2002; 59: 325-9
94. Sun QZ, Chen DF, Ding PL, Ma CM, Kakuda H, Nakamura N et al. Three new lignans, longipedunins A-C from Kadsura longipedunculata and their inhibitory activity against HIV-1 protease. Chem Pharm Bull 2006; 54: 129-32
95. Chen SW, Wang YH. Jin Y, Tian X, Zheng YT, Luo DQ et al. Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives. Bioorg Med Chem Lett 2007; 17: 2091-5
96. Zhu XK, Guan J, Xiao Z, Cosentino LM, Lee KH. Anti-AIDS agents. Part 61: anti-HIV activity of new podophyllotoxin derivatives. Bioorg Med Chem 2004; 12: 4267-73
97. Chen M, Kilgore N, Lee KH, Chen DF. Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora. J Nat Prod 2006; 69: 1697-701
98. Ovenden SPB, Wan SS, Sberna G, Tait RM, Rhodes D, Cox S et al. Glo-boidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 2004; 65: 3255-9
99. Piccinelli AL, Mahmood N, Mora G, Poveda L, De Simone F, Rastrelli L. Anti-HIV activity of dibenzylbutyrolactone-type lignans from Phenax species endemic in Costa Rica. J Pharm Pharmacol 2005; 57: 1109-15
100. McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998; 42: 140-6
101. Zhu K, Cordeiro ML, Atienza J, Robinson WE, Chow SA. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J Virol 1999; 73: 3309-16
102. King PJ, Robinson WE. Resistance to the anti-human immunodeficiency virus type 1 compound I-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998; 72: 8420-4
103. Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke TR et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol 2000; 58: 641-8
104. Sotriffer CA, Ni H, McCammon A. Active site binding modes of HIV-1 integrase inhibitors. J Med Chem 2000; 43: 4109-17
105. Lee DJ, Robinson WE. Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 2006; 50: 134-42
106. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Delivery Rev 1997; 23: 3-25
107. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates.] Med Chem 2002; 45: 2615-23
108. Kim SN, Lee JY, Kim HJ, Shin CG, Park H, Lee YS. Synthesis and HIV-1 integrase inhibitory activities of caffeoylglucosides. Bioorg Med Chem Lett 2000; 10: 1879-82
109. Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E et al. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 1997; 40: 3057-63
110. Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C et al. Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem 1999; 42: 1401-14
111. King PJ, Ma G, Miao W, Jia Q, McDougall BR, Reinecke MG et al. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J Med Chem 1999; 42: 497-509
112. Artico M, Di Santo R, Costi R, Novellino E, Greco G, Massa S et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation and molecular modeling. J Med Chem 1998; 41: 3948-60
113. Charvat TT, Lee DJ, Robinson WE, Chamberlin AR. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase. Bioorg Med Chem 2006; 14: 4552-67
114. Mazumder A, Raghava K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 1995; 49: 1165-70
115. Taher MM, Lammering G, Hershey C, Valerie K. Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression. Mol Cell Biochem 2003; 254: 289-97
116. Balasubramnyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/ nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-71
117. Appendino G, Ottino M, Marquez N, Bianchi F, Giana A, Ballero M et al. Arzanol, and anti-inflammatory and anti-HIV-1 phloroglucinol α-pyrone from Helichrysum italicum spp. microphyllum. J Nat Prod 2007; 70:608-12
118. Kim HJ. Woo ER. Shin CG. Hwang DJ. Park H. Lee YS. HIV-1 integrase inhibitory phenylpropanoid glycosides from Clerodendron trichotomum. Arch Pharm Res 2001; 24: 286-91
119. Dat TN. Bae K. Wamiru A. McMahon JB, Le Grice SFJ. Bona M et al. A dimeric lactone from Ardisia japonica with inhibitory activity for HIV-1 and HIV-2 Ribonuclease H. J Nat Prod 2007; 70: 839-41
120. O'Keefe BR. Biologically active proteins from natural product extracts. J Nat Prod 2001; 64: 1373-81
121. Peumans WJ. Hao Q, Van Damme EJM. Ribosome-inactivating proteins from plants: more than RNA N-glycosidases? Faseb J 2001; 15: 1493-06
122. Girbes T, Ferreras JM, Arias FJ, Stirpe F. Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev Med Chem 2004; 4: 461-76
123. Szalai K. Schöll I. Förster-Waldl E. Polito L, Bolognesi A, Untersmayr E et al. Occupational sensitization to ribosome-inactivating proteins in researchers. Clin Exp Allergy 2005; 35: 1354-60
124. Lee-Huang S. Huang PL. Bourinbaiar AS, Chen HC, Kung HF. Inhibition of the integrase of human immunodeficiency virus (HIV) type-1 by anti-HIV plant proteins MAP30 and CAP31. Proc Natl Acad Sci USA 1995; 92: 8818-22
125. Sun Y. Huang PL. Li JJ, Huang YQ, Zhang L. Huang PL et al. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem Biophys Res Commun 2001: 287: 983-94
126. Wang YX, Neamati N. Jacob J. Palmer I. Stahl SJ, Kaufman JD et al. Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 1999; 99: 433-42
127. Nicolas E, Beggs JM, Haltiwanger BM, Taraschi TF. A new class of DNA glycosylase apurinic/apyrimidinic lyases that act on specific adenines in single-stranded DNA. J Biol Chem 1998; 273: 17216-20
128. Huang PL. Sun Y. Chen HC. Kung HF. Huang PL. Lee-Huang S. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun 1999; 262: 615-23
129. McGrath MS. Hwang KM. Caldwell SE, Gaston I, Luk KC, Wu P et al. GLQ223 -an inhibitor of human immunodeficiency virus replication in acutely and chronically infected-cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci USA 1989; 86: 2844-8
130. Byers VS, Levin AS, Malvino A, Waites L, Robins RA, Baldwin RW. A phase-II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res Hum Retroviruses 1994; 10: 413-20
131. Chan SH. Shaw PC. Mulot SFC. Xu LH, Chan WL, Tarn SC et al. Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues. Biochem Biophys Res Commun 2000; 270: 279-85
132. Wang YY, Ouyang DY. Huang H, Chan H. Tam SC. Zheng YT. Enhanced apoptotic action of trichosanthin in HIV-1 infected cells. Biochem Biophys Res Commun 2005; 331: 1075-80
133. Au TK. Collins RA, Lam TL, Ng TB, Fong WP, Wan DCC. The plant ribo-some inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett 2000; 471: 169-72
134. Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res 2006; 71: 237-47
135. Balzarini J, Van Laethem K, Hatse S. Froeyen M, Peumans W, Van Damme E et al. Carbohydrate-bindings agents cause deletions of highly conserved glycosylation sites in HlV gp120 - a new therapeutic concept to hit the Achilles heel of HIV. J Biol Chem 2005; 280: 41005-14
136. Hu Q, Mahmood N, Shattock RJ. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanoverin-N and the impact on antibody neutralization. Virology 2007; 368: 145-54
137. Balzarini J. The α(l,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett 2007; 581: 2060-4
138. Balzarini J, Van Laethem K. Peumans WJ, Van Damme EJM, Bolmstedt A, Gago F et al. Mutational pathways, resistance profile, and side effects of cyanoverin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006; 80: 8411-21
139. Botos /. Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 2005; 88: 233-82
140. Saidi H. Nasreddine N. Jenabian MA, Lecerf M, Schols D. Krief D et al. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-d-mannose specific lectins: implication for microbicide development. J. Transl Med 2007; 5: 28-36
141. Balzarini J, Hatse S. Vermeire K. Princen K. Aquaro S, Pemo CF et al. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 2004; 48: 3858-70
142. Balzarini J, Van Laethem K. Hatse S, Vermeire K, De Clercq E. Peumans W et al. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J. Virol 2004; 78: 10617-27
143. Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E. Peumans W et al. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 1992; 18: 191-207
144. An J. Liu JZ, Wu CF, Li J, Dai L, Van Damme E et al. Anti-HIV l/ll activity and molecular cloning of a novel mannose/sialic acid-binding lectin from rhizome of Polygonatum cyrtonema Hua. Acta Biochem Biophyi Sin 2006; 38: 70-8
145. Wang HX. Ng TB. Examination of lectins, polysaccharopeptide, polysaccharide, alkaloid, coumarin and trypsin inhibitors for inhibitory activity against human immunodeficiency virus reverse transcriptase and glycohydrolases. Planta Med 2001; 67: 669-72
146. Charan RD, Munro MHC. 0'Keefe BR, Sowder RC, McKee TC, Currens MJ er al. Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii. J Nat Prod 2000; 63: 1170-4
147. Jiratchariyakul W, Wiwat C, Vongsakul M, Somanabandhu A, Leelamanit W. Fujii I et al. HIV inhibitor from Thai bitter gourd. Planta Med 2001; 67: 350-3
148. Wang H, Ng TB. Ginkbilobin, a novel antifungal protein from Ginkgo biloba seeds with sequence similarity to embryo-abundant protein. Biochem Biophys Res Commun 2000; 279: 407-11
149. Boyd MR, Gustafson KR. McMahon JB. Shoemaker RH, O'Keefe BR, Mori T et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41: 1521-30
150. Asres K, Seyoum A, Veeresham C, Bucar F, Gibbons S. Naturally derived anti-HIV agents. Phytother Res 2005; 19: 557-81
151. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SH1V89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19: 535-41
152. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20: 11-8
153. Giomarelli B, Provvedi R. Meacci F, Maggi T, Medaglini D, Pozzi G et al. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 2002; 16: 1351-6
154. Lagenauer LA, Berger EA. An anti-HIV microbicide comes alive. Proc Natl Acad Sci USA 2005; 102: 12294-5
155. Push O. Boden D, Hannify S, Lee F, Tucker LD, Boyd MR et al. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr 2005; 40: 512-20
156. Bokesch HR, O'Keefe BR, McKee TC, Pannell LK, Patterson GM, Gardella RS et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 2003; 42: 2578-84
157. Bewley CA, Cai M, Ray S, Ghirlando R, Yamaguchi M, Muramoto K. New carbohydrate specificity and HIV-1 fusion blocking activity of the cyanobacterial protein MVL: NMR, ITC and sedimentation equilibrium studies. J Mol Biol 2004; 339: 901-14
158. Mori T, O'Keefe BR, Sowder RC, Bringans S, Gardella R, Berg S et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280: 9345-53
159. Reutrakul V, Chanakul W, Pohmakotr M, Jaipetch T, Yoosook C, Kasisit J et al. Anti-HIV-1 constituents from leaves and twigs of Cratoxylum arborescens. Planta Med 2006; 72: 1433-5
160. Dharmaratne HRW, Tan CT, Marasinghe GPK, Pezzuto JM. Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. Planta Med 2002; 68: 86-7
161. Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Sophasan S, Yoosook C et al. Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med 2007; 73: 33-40
162. De Bruyne T, Pieters L, Deelstra H, Vlietinck A. Condensed vegetable tannins: biodiversity in structure and biological activities. Biochem Syst Ecol 1999; 27: 445-9
163. Khanbabaee K, van Ree T. Tannins: classification and definition. Nat Prod Rep 2001; 18: 641-9
164. Amouroux P, Jean D, Lamaison JL. Antiviral activity in vitro of Cupressus sempervirens on two human retroviruses HIV and HTLV. Phytother Res 1998; 12: 367-8
165. Ma CM, Nakamura N, Hattori M, Kakuda H, Qiao JC, Yu HL. Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia. J Nat Prod 2000; 63: 238-42
166. De Bruyne T, Pieters L, Witvrouw M, De Clercq E, Vanden Berghe D, Vlietinck AJ. Biological evaluation of proanthocyanidin dimers and related polyphenols. J Nat Prod; 1999; 62: 954-8
167. Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 2005; 1723: 270-81
168. Notka F, Meier G, Wagner R. Concerted inhibitory activities of Phyl-lanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res 2004; 64: 93-102
169. Zhang HJ, Huang NV, Cuong NM, Soejarto DD, PezzutoJM, Fong HHS et al. Sesquiterpenes and butenolides, natural anti-HIV constituents from Litsea verticillata. Planta Med 2005; 71: 452-7
170. Min BS, Hattori M, Lee KH, Kim YH. Inhibitory constituents against HIV-1 protease from Agastache rugosa. Arch Pharm Res 1999; 22: 75-7
171. Rashid MA, Gustafson KR, Boyd MR. HIV-inhibitory cembrane derivatives from a Philippines collection of the soft coral Lobophytum species. J Nat Prod 2000; 63: 531-3
172. Alam MS, Quader MA, Rashid AA. HIV-inhibitory diterpenoid from Anisomeles indica. Fitoterapia 2000; 71: 574-6
173. Barbosa JP, Pereira RC, Abrantes JL, Dos Santos CCC, Rebello MA, Frugulhetti ICPP et al. In vitro antiviral diterpenes from the Brazil brown alga Dicryora pfaffii. Planta Med 2004; 70: 856-60
174. Cirne-Santos CC, Teixeira VL, Castello-Branco LR, Frugulheti ICPP, Bou-Habid DC. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii. Planta Med 2006; 72: 295-9
175. Pereira HS, Leao-Ferreira LR, Moussatché N, Teieira VL, Cavalcanti DN, da Costa LJ et al. Effects of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on HIV-1 reverse transcriptase. Planta Med 2005; 71: 1019-24
176. Rukachaisirikul V, Pailee P, Hiranrat A, Tuchinda P, Yoosook C, Kasisit C et al. Anti-HIV-1 prostane triterpenes and digeranylbenzophenone from trunk bark and stems of Garcinia speciosa. Planta Med 2003; 69: 1141-6
177. Battinelli L, Mengoni F, Lichtner M, Mazzanti G, Saija A, Mastroianni CM et al. Effect of limonin and nomilin on HIV-1 replication on infected human mononuclear cells. Planta Med 2003; 69: 910-3
178. Chen DF, Zhang SX, Wang HK, Zhang SY, Sun QZ, Cosentino LM et al. Novel anti-HIV lancilactone C and related triterpenes from Kadsura lancilimba. J Nat Prod 1999; 62: 94-7
179. Xiao WL, Tian RR, Pu JX, Li X, Wu L, Lu Y et al. Triterpenoids from Schisandra lancifolia with anti-HIV-1 activity. J Nat Prod 2006; 69: 277-9
180. Huang L, Chen CH. Molecular targets of anti-HIV-1 triterpenes. Curr Drug Target Infect Disord 2002; 2: 33-6
181. Mengoni F, Lichtner M, Battinelli L, Marzi M, Mastroianni CM, Vullo V et al. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. Planta Med 2002; 68: 111-4
182. Sun IC, Shen JK, Wang HK, Cosentino LM, Lee KH. Anti-AIDS agents. 32. Synthesis and anti-HIV activity of betulin derivatives. Bioorg Med Chem Lett 1998; 8: 1267-72
183. Kashiwada Y, Wang HK, Nagao T, Kitanaka S, Yasuda I, Fujioka T. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J Nat Prod 1998; 61: 1090-5
184. Kashiwada Y, Nagao T, Hashimoto A, Ikeshiro Y, Okabe H, Cosentino LM et al. Anti-AIDS agents 38. Anti-HIV activity of 2-O-acylursolic acid derivatives. J Nat Prod 2000; 63: 1619-22
185. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004; 78: 922-9
186. Lee KH. Current developments in the discovery and design of new drug candidates from plant natural product leads. J Nat Prod 2004; 67: 273-83
187. Kashiwada Y, Chiyo J, Ikeshiro Y, Nagao T, Okabe H, Cosentino LM et al. 3,28-Di-O-(dimethylsuccinyl)-betulin isomers as anti-HIV agents. Bioorg Med Chem Lett 2001; 11: 183-5
188. Sami A, Taru M, Salme K, Jari YK. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 2006; 29: 1-13
189. Soler F, Poujade C, Evers M, Carry JC, Hénin Y, Bousseau A et al. Betulinic acid derivatives: A new class of specific inhibitors of human immunodeficiency virus type 1 entry. J Med Chem 1996; 39: 1069-83
190. Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelièvre Y et al. Betulinic acid derivatives: A new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. J Med Chem 1996; 39: 1056-68
191. Labrosse B, Treboute C, Alizon M. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J Virol 2000; 74: 2142-50
192. Holz-Smith SL, Sun IC, Jin L, Matthews TJ, Lee KH, Chen CH. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob Agents Chemother 2001; 45: 60-6
193. Huang L, Zhang L, Chen CH. Potential drug targets on the HIV-1 envelope glycoproteins, gpl20 and gp41. Curr Pharm Design 2003; 9: 1453-62
194. Huang L, Yuan X, Aiken C, Chen CH. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother 2004; 48: 663-5
195. Aiken C, Chen CH. Betulinic acid derivatives as HIV-1 antivirals. Trends Molecular Med 2005; 11:31-6